1. Home
  2. BNRG vs TSBX Comparison

BNRG vs TSBX Comparison

Compare BNRG & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNRG
  • TSBX
  • Stock Information
  • Founded
  • BNRG 2012
  • TSBX 2015
  • Country
  • BNRG Israel
  • TSBX United States
  • Employees
  • BNRG N/A
  • TSBX N/A
  • Industry
  • BNRG
  • TSBX
  • Sector
  • BNRG
  • TSBX
  • Exchange
  • BNRG Nasdaq
  • TSBX Nasdaq
  • Market Cap
  • BNRG 10.0M
  • TSBX 8.4M
  • IPO Year
  • BNRG 2022
  • TSBX 2023
  • Fundamental
  • Price
  • BNRG $1.31
  • TSBX $0.38
  • Analyst Decision
  • BNRG
  • TSBX Buy
  • Analyst Count
  • BNRG 0
  • TSBX 3
  • Target Price
  • BNRG N/A
  • TSBX $4.75
  • AVG Volume (30 Days)
  • BNRG 57.2K
  • TSBX 128.8K
  • Earning Date
  • BNRG 03-04-2025
  • TSBX 05-12-2025
  • Dividend Yield
  • BNRG N/A
  • TSBX N/A
  • EPS Growth
  • BNRG N/A
  • TSBX N/A
  • EPS
  • BNRG N/A
  • TSBX N/A
  • Revenue
  • BNRG N/A
  • TSBX N/A
  • Revenue This Year
  • BNRG N/A
  • TSBX N/A
  • Revenue Next Year
  • BNRG N/A
  • TSBX N/A
  • P/E Ratio
  • BNRG N/A
  • TSBX N/A
  • Revenue Growth
  • BNRG N/A
  • TSBX N/A
  • 52 Week Low
  • BNRG $0.60
  • TSBX $0.34
  • 52 Week High
  • BNRG $3.27
  • TSBX $3.88
  • Technical
  • Relative Strength Index (RSI)
  • BNRG 48.84
  • TSBX 44.54
  • Support Level
  • BNRG $1.19
  • TSBX $0.37
  • Resistance Level
  • BNRG $1.30
  • TSBX $0.42
  • Average True Range (ATR)
  • BNRG 0.09
  • TSBX 0.04
  • MACD
  • BNRG 0.00
  • TSBX 0.00
  • Stochastic Oscillator
  • BNRG 41.38
  • TSBX 37.25

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Share on Social Networks: